GLAD:NASDAQGladstone Capital Corporation Analysis
Data as of 2026-06-13 - not real-time
$19.39
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Gladstone Capital (GLAD) trades at $19.39, comfortably above its recent support of $18.64 but below the 30‑day DCF fair value of $30.01, implying a potential upside of roughly 13 %. The stock’s P/E of 10.4 is well under the industry average of 16.8, and the price‑to‑book of 0.91 suggests a discount to net asset value, supporting an undervalued view. However, the dividend yield is exceptionally high at 9.5 % while the payout ratio exceeds 100 %, and operating cash flow is negative, raising concerns about the sustainability of the dividend. Technical indicators are mixed: RSI sits at 53 (neutral), the MACD histogram is slightly negative with a bearish signal, and volume trends are decreasing, indicating limited short‑term momentum. Recent material news includes a Zacks Rank upgrade to a “Buy,” which could attract income‑focused investors ahead of the upcoming ex‑dividend date on June 23.
Risk factors are notable: 30‑day volatility is around 25 %, the max drawdown exceeds 43 %, and the company carries $392 M of debt against just $3.4 M of cash, yielding a high debt‑to‑equity ratio. Nonetheless, beta is low (≈0.58), suggesting limited market‑wide risk, and the sector—financial services/asset management—exhibits medium risk. Balancing the attractive valuation and dividend against cash‑flow weakness and leverage leads to a cautious but optimistic stance for medium‑term investors.
Risk factors are notable: 30‑day volatility is around 25 %, the max drawdown exceeds 43 %, and the company carries $392 M of debt against just $3.4 M of cash, yielding a high debt‑to‑equity ratio. Nonetheless, beta is low (≈0.58), suggesting limited market‑wide risk, and the sector—financial services/asset management—exhibits medium risk. Balancing the attractive valuation and dividend against cash‑flow weakness and leverage leads to a cautious but optimistic stance for medium‑term investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bearish MACD signal
- High dividend yield but questionable sustainability
- Decreasing trading volume limiting short‑term momentum
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued relative to DCF fair value and industry multiples
- Attractive dividend yield for income investors
- Zacks Rank upgrade signaling improved earnings expectations
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Elevated leverage and negative operating cash flow
- Potential dividend cuts if cash generation does not improve
- Stable sector exposure with low beta reducing market risk
Key Metrics & Analysis
Financial Health
Revenue Growth20.50%
Profit Margin44.05%
P/E Ratio10.4
ROE8.40%
ROA5.18%
Debt/Equity75.84
P/B Ratio0.9
Op. Cash Flow$-93471000
Free Cash Flow$34.9M
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI53.2
Support$18.64
Resistance$19.65
MA 20$19.23
MA 50$18.98
MA 200$20.02
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Fair Value$30.01
Target Price$22.00
Upside/Downside13.46%
GradeUndervalued
TypeValue
Dividend Yield9.52%
Risk Assessment
Beta0.58
Volatility25.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
ZIONP
Zions Bancorporation N.A. - Depositary Shares each representing a 1/40th ownership interest in a share of Series A Floating-Rate Non-Cumulative Perpetual Prefer
STOCKWENN
Wen Acquisition Corp
STOCKCOIN
Coinbase Global, Inc.
STOCKTTRX
Turn Therapeutics Inc.
STOCKQNTM
Quantum Biopharma Ltd.
STOCKPSFE
Paysafe Limited
STOCKThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.